<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619176</url>
  </required_header>
  <id_info>
    <org_study_id>acumicro</org_study_id>
    <nct_id>NCT01619176</nct_id>
  </id_info>
  <brief_title>Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood</brief_title>
  <official_title>Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acupuncture is used and recommended by the WHO for the treatment of Rheumatoid Arthritis.

      The molecular bases of this recommendation are not known, the investigators want to compare
      with the usage of high-throughput molecular technologies the variations occurring in patients
      treated with acupuncture and conventional treatment with the ones treated with conventional
      treatment only. The investigators observe the variations in blood and in the gut microbiome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ACR20-50-70</measure>
    <time_frame>3 weeks and 3 months</time_frame>
    <description>ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters:
acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire
the number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SDAI</measure>
    <time_frame>3 weeks and 3 months</time_frame>
    <description>simplified disease activity index SDAI, is the numerical sum of five outcome parameters: tender and swollen joint count (based on a 28-joint assessment), patient and physician global assessment of disease activity [visual analogue scale (VAS) 0-10 cm] and level of C-reactive protein (mg/dl, normal &lt;1 mg/dl)
SDAI≦3.3 is the threshold to consider remission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate: 7.5mg/week to 15mg/week for 3 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-steroidal anti-inflammatory drug (NSAID)</intervention_name>
    <description>NSAID: 100mg twice a day for 3 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>leflunomide: 20mg/day for 3 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate: 7.5mg/week to 15mg/week for 3 months</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-steroidal anti-inflammatory drug (NSAID)</intervention_name>
    <description>NSAID: 100mg twice a day for 3 months</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leflunomide</intervention_name>
    <description>leflunomide: 20mg/day for 3 months</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Acupuncture</intervention_name>
    <description>30 minutes acupuncture every other day for 3 months.
Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20.</description>
    <arm_group_label>Acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient should be diagnosed as the first or second stage of rheumatoid Arthritis
             (RA) and checked with X ray for additional diagnose.

          -  diagnosed for RA according to ACR(1987)

          -  the patient should be in the active stage of the disease, defined as：

               1. swollen joints &gt;3

               2. tender joints &gt; 5

               3. any one of the following： (c1.) morning stiffness lasting more than 45 minutes
                  (c2.) Erythrocyte Sedimentation Rate (ESR) &gt;= 28mm/h (c3.) C-reactive protein
                  (CRP)&gt;= 12mg/L

          -  Should not be resistant to MTX nor leflunomide

          -  Blood test should satisfy:

               1. Hemoglobin (Hb)&gt;=85g/L

               2. White cell &gt;=3.5 10+9/L

               3. Platelets &gt;= 100 10+9/L

               4. Liver function: serum alanine aminotransaminase (ALT), aspartate transaminase
                  (AST) and total bilirubin (TBil) should be less than 1.5 times the upper limit of
                  normal (ULN)

               5. Kidney function: Serum creatinine (Cr) level should be less than ULN.

               6. Pregnancy test should be negative

          -  should be positive for anti-cyclic citrullinated protein antibodies (anti-CCP).

          -  should agree to sign the informed consent

        Exclusion Criteria:

          -  Serious diseases affecting liver, kidney, heart and lung, or diseases related to
             hematologic，endocrine and nervous systems. .

          -  Be treated by MTX or Leflunomide in the last 3 months.

          -  Be treated with cortical hormone （could be intramuscular injection, intravenous
             injection or injection to articular cavity） in the last 4 weeks.

          -  Be treated with biological agents, such as antagonist of TNF-alpha,IL-6, and CD20 mono
             antibody in the last 3 months.

          -  Be treated by chronic medicine, such as immunosuppressive agent, Penicillamine,
             chloroquine and gold based Disease-modifying antirheumatic drugs (DMARDs) in the last
             3 months.

          -  Pregnant and breast-feeding woman

          -  Having history of serious drug allergy

          -  In the acute or chronic phase of infection (such as lung diseases)

          -  Easy bleeding patients or patients with local skin infection (only for acupuncture)

          -  The patients cannot accept acupuncture (only for acupuncture)

          -  Be treated with acupuncture in the past 3 months（only for acupuncture）.

          -  No pregnant and breast-feeding woman.

          -  No history of serious drug allergy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Nardini, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Key laboratory of Computational Biology, Chines Academy of Sciences - Max Planck Institute - Partner Institute for Computational Biology (CAS MPG PICB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai GuangHua Hospital of integrated traditional and western medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Christine Nardini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>blood</keyword>
  <keyword>gut intestinal microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

